DUBLIN--(BUSINESS WIRE)--Jul 31, 2018--The "Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Ongoing Global Clinical Trials Analysis and Outlook" report has been added to ResearchAndMarkets.com's offering.

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) ongoing clinical trials report provides comprehensive analysis and trends in global Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) disease clinical trials. The research work analyzes the ongoing Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) clinical trial trends across countries and companies.

The report focuses on drugs and therapies being evaluated for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) treatment in active clinical development phases including phase 1, phase 2, phase 3 and phase 4 clinical trials. The report also provides trials information by region, key countries, enrollment, phases, trial status and sponsor types.

Our experienced database team dynamically updates the clinical trials data from several sources including Clinical trial registries, conferences, journals and company releases etc. Further, data is presented in user friendly manner to enable readers quick access to Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) clinical trials.

Scope of the Report:

Ongoing Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) clinical trials across regions Trial information by Phase and Subjects recruited Trial information by status, type, sponsor type Drugs used for treatment of Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Both observational and interventional trials analyzed Leading companies and universities participating in Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) clinical trials

Reasons to Buy:

Track competition and design competitive advantages Identify right partners to associate with for further research Evaluate potential opportunities available in further clinical trials of the disease Formulate business development strategies through success rates of clinical trials Identify quick markets for recruiting subjects based on trials count by each market

Key Topics Covered:

1 Table of Contents

2 Key Findings, 2018

3 Clinical Trials Trends to 2022

4 Country Level Analysis

5 Company Level Analysis

6 Enrolment Trends to 2022

7 Ongoing Trials- Phase, ID, Title, Location, Type, Duration, Recruitment Status, Company Details

8 Appendix

For more information about this report visit https://www.researchandmarkets.com/research/frpzq9/global_dravet?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180731005538/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Central Nervous System Drugs,Clinical Trials

KEYWORD:

INDUSTRY KEYWORD: HEALTH CLINICAL TRIALS PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 07/31/2018 08:42 AM/DISC: 07/31/2018 08:42 AM

http://www.businesswire.com/news/home/20180731005538/en